Nearly Half of Pharmaceutical and Biotechnology Chief IP Counsel Report Active Patent Infringement Litigation, Consero Survey Reveals

March 2013 Procurement & Strategic Sourcing Report
March 8, 2013
Corporate Counsel: Pharma, Biotech IP Counsel Expect a Litigious Year
March 13, 2013

Nearly Half of Pharmaceutical and Biotechnology Chief IP Counsel Report Active Patent Infringement Litigation, Consero Survey Reveals

Majority of Participants Surveyed Indicate “Very High” Likelihood That Their Company Will File A Claim for Patent Infringement in The Next 12 Months

BETHESDA, Md- (March 13, 2013) – According to a new survey, nearly half of Pharmaceutical and Biotechnology Chief IP Counsel disclosed that their companies are currently a party to patent infringement litigation, and 43 percent expect to file a claim for patent infringement in the year ahead, according to the 2013 Chief Intellectual Property Counsel Data Survey for the Pharmaceuticals and Biotechnology Industry. The survey was compiled by Consero Group, an international leader in creating high-level, invitation-only events for senior executives.

“Patent infringement is a critical issue for today’s corporations, as the protection of intellectual property can mean the difference between success and failure, particularly within the pharmaceutical and biotech industries,” said Paul Mandell, Founder & CEO of Consero. “Litigation is an essential component of IP strategy, and 2013 is likely to remain a highly litigious environment in these industries and beyond.”

The survey also found that Pharmaceutical and Biotechnology Chief IP Counsel have good access to corporate leadership, with 95 percent of respondents reporting a sufficient level of access to their CEOs and 79 percent reporting sufficient access to their Boards of Directors. They also have access to substantial resources, as the median budget of surveyed participants was between $2.5 and $5 million. Staff size remained stable in 2012 compared to 2011, with 45 percent reporting no change in their staff size. The group is well compensated, with median salary of $250,000 to $274,999 and with over 10 percent reporting a salary of $400,000 to $500,000.

“With most of the respondents expecting to file litigation of their own, the trend of generally increasing budgets and steady or increasing departmental staff size to accommodate swelling IP demand seems all but certain to continue,” said Mandell.

The survey was composed of 12 questions that were posed to all Fortune 1000 Chief Intellectual Property Counsel who were in attendance at Consero’s Pharmaceutical and Biotechnology IP Forum in December 2012. A total of 38 responses were provided.

About Consero
Founded in 2010, Consero is an international leader in creating industry-specific events for senior-level executives in industries that include: Legal, Compliance, Shared Services, Customer Experience, Finance, IT, HR, and Procurement. With operations in the U.S. and in Europe, Consero is best known for transforming the executive experience through intimate, invitation-only programs in a sophisticated learning environment with high-level content.  For more information on Consero, please visit